Introduces fast-track development strategy at BIX 2026
Proposes cutting development time from 13 months to 9.5 months
Improves productivity by optimizing culture and purification processes

Samsung Biologics has unveiled its contract development (CDO) capabilities in bispecific and multispecific antibodies, next-generation biopharmaceuticals. The company presented its ability to optimize manufacturing processes for complex antibody structures, improve quality control systems, and use a fast-track development approach to reduce the development timeline from 13 months to 9.5 months.


Lee Taehee, an executive director at Samsung Biologics, said on October 28 at BioPlus-Interphex Korea 2026 (BIX 2026), held at COEX in Gangnam-gu, Seoul, “Simply modifying the existing monoclonal antibody process is not enough to develop bispecific antibodies.” He stressed that “it is important to understand the structure and characteristics of the molecule and apply a development strategy suited to it.”


Lee Taehee, executive vice president at Samsung Biologics, speaks on “Beyond Complexity: Rapid Development of Bispecific and Multispecific Antibodies” at BioPlus-Interphex Korea 2026 (BIX 2026), held at COEX in Gangnam-gu, Seoul, on the 28th. Photo by Lee Seongmin.

Lee Taehee, executive vice president at Samsung Biologics, speaks on “Beyond Complexity: Rapid Development of Bispecific and Multispecific Antibodies” at BioPlus-Interphex Korea 2026 (BIX 2026), held at COEX in Gangnam-gu, Seoul, on the 28th. Photo by Lee Seongmin.

View original image

Bispecific antibodies are designed to bind to two different targets simultaneously. They can offer therapeutic effects that are difficult to achieve with conventional monoclonal antibodies, but their complex structures make manufacturing and quality control challenging. Impurities can arise as protein chains combine, making it necessary to design processes suited to the molecule’s characteristics from the development stage.


Samsung Biologics applies molecule-specific manufacturing and quality control (CMC) strategies throughout the entire process, from cell line development and cultivation to purification, formulation, and analysis. This includes adjusting the expression ratios of protein chains during the initial cell line development stage and optimizing culture medium components and process conditions to increase both yield and quality during cultivation.


The company also presented examples of process improvements. In one bispecific antibody development project, adjustments to cultivation conditions reduced the fragmentation rate—the rate at which proteins break down into smaller pieces—by approximately 34 percentage points, while increasing antibody production by approximately 20%. In another case, the company reduced the proportion of protein aggregates by approximately 14 percentage points while maintaining production levels.


In a development project involving antibody proteins clumping together to form high-molecular-weight aggregates, optimized purification conditions and separation processes lowered the aggregate proportion from approximately 50% to around 1%. The company also presented cases in which purification methods tailored to the characteristics of the impurities achieved purity levels of 98% and 97% or higher, respectively.


Lee Taehee, an executive director at Samsung Biologics, gives a presentation titled "Beyond Complexity: Rapid Development of Bispecific and Multispecific Antibodies" at BioPlus-Interphex Korea 2026 (BIX 2026), held at COEX in Gangnam-gu, Seoul, on the 28th. Photo by Lee Seongmin.

Lee Taehee, an executive director at Samsung Biologics, gives a presentation titled "Beyond Complexity: Rapid Development of Bispecific and Multispecific Antibodies" at BioPlus-Interphex Korea 2026 (BIX 2026), held at COEX in Gangnam-gu, Seoul, on the 28th. Photo by Lee Seongmin.

View original image

Lee said, “Even molecules with the same structure can differ in the characteristics of their main impurities,” adding that “it is important to understand the molecule’s structure and the characteristics of its impurities, and to establish a purification strategy suited to them.”


Alongside these process optimization technologies, Samsung Biologics has an operating system that can shorten development timelines. The company performs some cell line development and analytical work in parallel, rather than sequentially as before, and works with its quality control (QC) department from the early stages of development to jointly verify the suitability of analytical methods. The company said this approach can reduce risks associated with analytical method technology transfer and shorten related timelines by up to three months.


The company has also established its own master cell bank (MCB) manufacturing capabilities, which it uses to prepare for clinical drug production. By combining timeline-reduction techniques applied to individual processes with parallel development, Samsung Biologics presented a fast-track strategy that can reduce the development process—from vector construction for gene expression to the submission of an investigational new drug (IND) application—from approximately 13 months to 9.5 months.



Lee stressed, “There is no single solution that works for every complex antibody,” adding that “it is important to apply an integrated strategy tailored to each molecule’s characteristics, from cell line development and cultivation to purification, formulation, and analysis.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing